+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Coinfection with HIV and hepatitis C virus in injection drug users and minority populations.

      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Antiretroviral Therapy, Highly Active, adverse effects, Drug-Induced Liver Injury, HIV Infections, complications, drug therapy, epidemiology, Hepatitis C, Humans, Liver Diseases, virology, Minority Groups, Substance Abuse, Intravenous, therapy

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is common. In the United States, it has been estimated that 25% of persons infected with HIV are also infected with HCV. The prevalence of coinfection with HIV and HCV is highest among those infected via percutaneous routes. In fact, in urban areas in the United States, 50%-90% of persons infected with HIV via injection drug use are coinfected with HCV. In addition, limited data from drug treatment centers in these urban areas suggest that the prevalence of coinfection with HIV and HCV may be highest among African Americans and Hispanics. Little information is available with regard to the epidemiology of coinfection with HIV and HCV among injection drug users (IDUs) or minority populations. Likewise, although there is a growing body of data on the potential complexities of treating HCV among IDUs and the poor response to current anti-HCV treatment among African Americans, few data address the therapy of coinfection with HIV and HCV among IDUs and minority populations.

          Related collections

          Author and article information


          Comment on this article